Validation is not a one-time test performed before a pharmaceutical production line goes live. Under GMP, industrial automation for pharmaceuticals must be shown to perform consistently, protect product quality, preserve trustworthy records, and remain under control after changes, maintenance, software updates, and unexpected events.

A programmable logic controller, SCADA platform, historian, electronic batch record system, sensor network, or variable-speed drive may all be technically reliable while still being unsuitable for GMP use. The validation question is broader: can the manufacturer demonstrate that the system does what it is intended to do, prevents or detects failures that could affect product quality, and creates records that can be reviewed with confidence?

The strongest validation programs start with intended use and quality risk, then build testing and documentation around the functions that matter. They do not attempt to prove that every automation feature is equally important.

Begin with intended use, not with a vendor test package

Supplier documentation, factory acceptance testing, and standard commissioning records are useful inputs, but they do not validate a pharmaceutical process on their own. A vendor can show that a controller starts motors, receives signals, or displays alarms. The pharmaceutical manufacturer must show that those functions support the approved process and its GMP controls in the installed environment.

Define intended use in practical language before writing test scripts. For example, a mixing skid may need to control agitation speed within an approved operating range, prevent a batch from progressing when a critical utility is unavailable, record selected process values, and ensure that only authorized users can change control settings. A warehouse monitoring system may need to capture temperature readings, alert responsible personnel when limits are exceeded, retain a reviewable event history, and avoid losing data during a communications interruption.

Vague statements such as “the system controls the process” create weak validation. A usable intended-use statement identifies the process step, the relevant quality risk, the automation function, the expected operating state, and the record or action needed to demonstrate control.

Apply a risk-based validation scope

Not every device connected to a pharmaceutical network has the same GMP impact. Treating all components identically produces excessive documentation while drawing attention away from the controls that protect the batch. A risk assessment should connect the automation function to potential consequences for product quality, patient safety, data integrity, and the ability to make a valid disposition decision.

This assessment should also identify indirect dependencies. A critical control loop can fail because of a network switch, server, power supply, clock source, virtual machine, instrument calibration status, or configuration backup. Validation scope should follow the path from measurement to control action and finally to the GMP record, rather than stopping at the visible operator screen.

A common error is calling a system “non-critical” because it does not directly release product. If its failure can prevent detection of an excursion, allow an unauthorized recipe change, obscure an alarm response, or make batch evidence unreliable, it still requires meaningful control.

Translate GMP expectations into clear requirements

Requirements are the bridge between process knowledge and testing. They should be understandable to process owners, automation engineers, and reviewers, while remaining specific enough to verify. Each requirement needs a traceable basis: a process requirement, safety function, quality control, operating procedure, or data-integrity need.

For industrial automation for pharmaceuticals, requirements commonly cover the following areas:

• Process control ranges, setpoints, tolerances, and permitted operating modes.
• Interlocks that prevent unsafe or non-compliant process progression.
• Alarm priorities, annunciation, acknowledgement rules, and response expectations.
• User roles, access approval, password or authentication controls, and account removal.
• Electronic records, audit trails, time stamps, data retention, and record retrieval.
• Interfaces between PLCs, SCADA systems, historians, laboratory systems, and batch-record applications.
• Backup, restoration, system recovery, and management of software and configuration versions.
• Behavior during power loss, sensor failure, network interruption, or restart.

Requirements should distinguish between functions that are necessary for GMP operation and optional features that are available in the software. A feature does not need validation merely because it exists. Conversely, a function cannot be excluded simply because it was implemented through custom logic rather than a standard product feature.

Build evidence across the lifecycle

Validation is more credible when evidence is created as decisions are made, rather than reconstructed shortly before an inspection. The exact document names and approval workflow can vary, but the underlying lifecycle should be coherent.

Early records normally establish the system boundary, intended use, process and data risks, responsibilities, and validation approach. Design documentation should explain how the approved requirements are implemented. This may include functional descriptions, control narratives, alarm lists, network diagrams, input/output lists, configuration specifications, interface definitions, and cybersecurity design decisions where they affect system integrity or availability.

Testing then demonstrates that the delivered solution matches the approved design and performs in its real operating context. Factory testing can efficiently verify standard panels, PLC logic, and basic software configuration before shipment. Site testing is still needed because field wiring, instruments, utilities, local network behavior, installed versions, environmental conditions, and operational procedures can change the actual outcome.

Traceability is essential. Each important requirement should lead to one or more test cases, and each test result should point back to the requirement it supports. When a requirement is not tested directly, the justification should be explicit. A traceability matrix is useful because it reveals two costly problems early: requirements with no evidence and test scripts with no clear GMP purpose.

Test normal operation, failure modes, and recovery

A test that only confirms a pump starts and stops has limited value when the GMP risk lies in what happens when a signal becomes unreliable or an operator makes an incorrect selection. Test scripts should challenge the system in realistic conditions.

For a critical control loop, this can include simulating an out-of-range signal, disconnecting a communication path where practical, confirming alarm generation, verifying the required interlock, checking what the operator sees, and confirming that the event is recorded. For a batch sequence, test incorrect step requests, repeated commands, interruption and restart, manual intervention, and the route used to resolve exceptions.

Recovery testing deserves particular attention. After a controlled restart, power interruption, server failover, or restore from backup, the system must return to a known state without creating ambiguous records or silently changing critical settings. The objective is not merely to prove that the application opens. It is to show that operations can resume under defined conditions and that the electronic evidence remains complete.

Data integrity is part of control-system validation

In pharmaceutical manufacturing, a value displayed on a screen is not automatically a trustworthy record. Data integrity controls need to cover the full path: how a value is generated, transferred, stored, changed, reviewed, and retrieved.

Start by identifying the data that supports quality decisions. These may include critical process parameters, alarm events, operator actions, recipe versions, status changes, audit-trail entries, and batch execution records. For each type of data, determine who can create or modify it, whether changes are recorded with context, how time is assigned, how long it is retained, and how it can be reviewed.

Shared user accounts are particularly difficult to defend because they weaken accountability. The same concern applies to unrestricted engineering access on production systems, unapproved use of local administrator accounts, and informal changes made directly in a controller or SCADA configuration. Access must reflect actual job responsibilities, and privileged access needs stronger procedural control.

Audit trails should be meaningful, not simply enabled. Reviewers must be able to identify what changed, who made the change, when it happened, and whether the change required approval or assessment. A system that retains technical events but cannot support an efficient review process may still leave an important GMP gap.

Commissioning, calibration, and validation have different purposes

These activities overlap, but they should not be treated as interchangeable. Commissioning establishes that equipment and utilities are installed, connected, and operating as engineered. Calibration establishes that an instrument or measuring device performs within its accepted condition. Validation establishes that the automated process and its records consistently support their intended GMP use.

Using commissioning results within validation is efficient when the evidence is reliable, approved for its intended purpose, and relevant to the requirement being demonstrated. Repeating every electrical check in a validation protocol usually adds little value. However, a commissioning record cannot replace testing of an electronic signature workflow, a critical alarm response, a recipe permission rule, or a data-recovery process.

For sensors and analyzers, validation should link instrument status to the process control strategy. A calibrated sensor can still be used incorrectly if the engineering range, scaling, alarm limits, or control logic are wrong. Conversely, correct PLC logic cannot compensate for an instrument that is not maintained within its defined condition.

Manage configuration changes as validated changes

Automation systems continue to evolve after release. A firmware update, replacement PLC, new motor drive, revised alarm limit, network redesign, instrument substitution, or small logic change can alter validated behavior. The risk is often not the change itself, but the assumption that it is too minor to assess.

Change control should identify the affected requirements, process risks, interfaces, records, cybersecurity controls, operating procedures, and training needs. It should also define the evidence needed before release. The appropriate response may range from documented review and targeted functional testing to broader regression testing when the affected component supports multiple critical functions.

Configuration management makes this practical. Approved PLC programs, SCADA graphics, recipes, parameter sets, drive settings, database schemas, and system images should be identifiable and recoverable. Without a controlled baseline, it becomes difficult to prove what was tested or to restore the validated state after a fault.

Prepare for inspection by making the system understandable

Inspection readiness is not achieved by collecting more documents than necessary. It comes from a consistent story: the process risks were understood, requirements were defined, the design addressed those requirements, tests demonstrated the intended behavior, deviations were investigated, and later changes remained controlled.

Documentation should let a reviewer move from a critical process function to the relevant requirement, design element, test evidence, deviation record, and current configuration. This is especially important where control systems depend on electrical infrastructure, industrial networks, drives, and distributed monitoring platforms. Technical intelligence on automation architecture and power-system reliability can help teams identify dependencies early, but the final validation rationale must always be tied to the actual pharmaceutical process and its quality risks.

Questions that expose weak validation early

• Can the team explain which automated functions affect product quality or record reliability, and why?
• Are critical alarms tested with the real operator response and the required downstream action?
• Can a reviewer reconstruct a batch-relevant event from the source signal through to the stored record?
• Is there evidence that backup restoration preserves the approved configuration and required data?
• Are manual overrides, engineering access, and emergency operating modes controlled and periodically reviewed?
• Does each approved software or configuration version have a clear release status?

If these questions cannot be answered with current evidence, adding more generic test scripts is rarely the best first step. Clarify the intended use, reassess the quality risks, establish the missing requirements, and test the specific gaps. That approach creates a validation package that is more useful in day-to-day operations as well as during GMP review.